Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 152 of the 158 references it cites were found in a registry or an index; 92 of the 144 sources its claims cite were checked for support.

Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma

Open access

Abstract

Malignant pleural mesothelioma (MPM) is a lethal and rare cancer, even if its incidence has continuously increased all over the world. Asbestos exposure leads to the development of mesothelioma through multiple mechanisms, including chronic inflammation, oxidative stress with reactive oxygen species (ROS) generation, and persistent aberrant signaling. Together, these processes, over the years, force normal mesothelial cells’ transformation. Chronic inflammation supported by “frustrated” macrophages exposed to asbestos fibers is also boosted by the release of pro-inflammatory cytokines, chemokines, growth factors, damage-associated molecular proteins (DAMPs), and the generation of ROS. In addition, the hypoxic microenvironment influences MPM and immune cells’ features, leading to a significant rewiring of metabolism and phenotypic plasticity, thereby supporting tumor aggressiveness and modulating infiltrating immune cell responses. This review provides an overview of the complex tumor–host interactions within the MPM tumor microenvironment at different levels, i.e., soluble factors, metabolic crosstalk, and oxidative stress, and explains how these players supporting tumor transformation and progression may become potential and novel therapeutic targets in MPM.

Overview

CoChat Summary

TL;DR

This review synthesizes how chronic inflammation, oxidative stress/ROS, and metabolic plasticity jointly drive a pro-tumorigenic, immunosuppressive microenvironment in malignant pleural mesothelioma (MPM). It highlights candidate therapeutic targets including TGF-β, IL-6, TNF-α/HMGB1, redox-sensitive factors, the adenosine pathway, and BAP1-related metabolic reprogramming.

Key findings

  • Asbestos-induced “frustrated phagocytosis” by macrophages causes ROS release, pro-inflammatory cytokines/chemokines (IL-8, IL-6, CCL2/MCP-1, G-CSF, GM-CSF, MIP-1α), DAMPs including HMGB1, and chronic inflammation that promotes mesothelial transformation; M2-like macrophages (CD163+, CD206+, IL-4Rα+) infiltrate MPM.
  • TGF-β family members (gremlin-1, activin A, TGF-β) support MPM progression; TGF-β1 mRNA correlated with worst prognosis in 74 mesothelioma tumors. In a fresolimumab trial, no radiographic responses were observed, median progression time was 1.4 months, and 10 patients progressed after only two cycles. IL-6 is produced by mesothelioma cells, but its autocrine growth role is conflicting; it may mediate resistance to classic cytotoxic agents.
  • Oxidative stress/ROS from asbestos iron content and inflammatory cells activates antioxidant pathways involving Nrf2, Ref-1, and FOXM1; a ROS–TGF-β1 axis promotes EMT, and iron/ferritin biology (FHC, FTL) plus ferroptosis resistance are implicated in asbestos-related carcinogenesis.
  • Metabolic plasticity includes hypoxia-driven GLUT-1/HIF-1α/VEGF/PI3K-mTOR upregulation, LAT1-mediated amino acid deprivation of T cells, IDO-mediated tryptophan degradation, adenosine/CD39/CD73 signaling, and BAP1 loss shifting metabolism from TCA/OXPHOS toward aerobic glycolysis with increased extracellular lactate.

Methods

  • Narrative review; no primary experiments, systematic search strategy, or meta-analysis are described. It synthesizes published literature on MPM tumor–host interactions, soluble factors, oxidative stress, and metabolic crosstalk.
  • Evidence cited includes preclinical models, mesothelioma cell lines, patient pleural effusions/tumors, and clinical trials such as CheckMate 743 and a fresolimumab study. No sample size or literature-search details are stated.

Limitations

  • The paper does not state a formal limitations section. Stated caveats include conflicting results on IL-6 as an autocrine growth factor, very little information about the adenosine pathway in MPM, and significant intra-tumoral and inter-tumoral heterogeneity between patients.
  • Evident from the text: as a narrative review, it lacks systematic search and quality appraisal, and many mechanistic conclusions rely on heterogeneous preclinical or non-MPM findings; therapeutic targeting of these pathways remains largely speculative.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cells12162048

Cites

152 of 152 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Cellular and soluble factors involved in asbestos-induced mesothelial cell transformation. Upon exposure to asbestos, necrotic cells and monocytes/macrophages release/secrete soluble factors creating an inflamed environment able to support the onset and the progression of mesothelioma. See main text for abbreviations. Created with BioRender.com.
Figure 1 Cellular and soluble factors involved in asbestos-induced mesothelial cell transformation. Upon exposure to asbestos, necrotic cells and monocytes/macrophages release/secrete soluble factors creating an inflamed environment able to support the onset and the progression of mesothelioma. See main text for abbreviations. Created with BioRender.com.CC BY · PubMed Central
Figure 2 Key players within the MPM microenvironment. The complex landscape of MPM-TME is characterized by the interconnection between cancer and stromal/immune cells to create a permissive and pro-tumorigenic environment. Hypoxic conditions and oxidative stress, chronic inflammation, and soluble factors trigger metabolic reprogramming. Moreover, also aberrant signaling and DNA damage pathways, as well as mutations in specific genes such as BAP1, contribute to a switch toward glycolytic metabolism (Warburg effect) in tumor and in immune cells, promoting MPM cell growth and progression. Lactate and immunosuppressive molecules, including IDO and ADO excreted in the microenvironment, lead to MPM cells’ adaptation, survival, metastatization, and escape from immune control. See main text for abbreviations. Created with BioRender.com.
Figure 2 Key players within the MPM microenvironment. The complex landscape of MPM-TME is characterized by the interconnection between cancer and stromal/immune cells to create a permissive and pro-tumorigenic environment. Hypoxic conditions and oxidative stress, chronic inflammation, and soluble factors trigger metabolic reprogramming. Moreover, also aberrant signaling and DNA damage pathways, as well as mutations in specific genes such as BAP1, contribute to a switch toward glycolytic metabolism (Warburg effect) in tumor and in immune cells, promoting MPM cell growth and progression. Lactate and immunosuppressive molecules, including IDO and ADO excreted in the microenvironment, lead to MPM cells’ adaptation, survival, metastatization, and escape from immune control. See main text for abbreviations. Created with BioRender.com.CC BY · PubMed Central

Verification

Claims the paper makes

61 Valid · 4 Not valid · 28 Not checked · 25 Own results and interpretations

65 more claims · 29 with their cited sources checked

Create a free account to see all 118 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 46
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Cited by

See all 39

Metadata

Authors
Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V.
Affiliations
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
Corresponding author
Audrito, Valentina
Venue
Cells
Publisher
MDPI AG
Published
2023-08-11
Volume
12
Issue
16
Pages
2048
ISSN
2073-4409 (ISSN-L)
OpenAlex
W4385759859
Cited by
39
References
158
Citations by year
2026: 12 · 2025: 17 · 2024: 10
FWCI
1.80
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
the Associazione Italiana di Ricerca sul Cancro (MFAG-2021 #26004)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
malignant pleural mesothelioma, asbestos exposure, chronic inflammation, oxidative stress, reactive oxygen species, tumor microenvironment, metabolic plasticity, tumor hypoxia, tumor-associated macrophages, damage-associated molecular patterns, antitumor immunity, metabolic crosstalk, tumor progression, therapeutic target
MeSH terms
Mesothelioma, Malignant, Humans, Inflammation, Reactive Oxygen Species, Oxidative Stress, Tumor Microenvironment, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.